Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02581072 · ClinicalTrials.gov registry record · Phase 1
A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204
A Phase 1 study of Acne Vulgaris, sponsored by Novan.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT02581072: Completed Phase 1 study of Acne Vulgaris, sponsored by Novan.
NCT02581072 is a Phase 1 study of Acne Vulgaris that has completed, run by Novan. The registered enrollment target is 56 participants, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02581072, a Phase 1 study of Acne Vulgaris, has completed, sponsored by Novan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
A Double-Blind, Double-Dummy, Randomized, 4-Period Crossover Study to Define the ECG Effects of SB204 Using a Clinical and Supratherapeutic Dose Compared with Placebo and Moxifloxacin (a Positive Control) in Subjects with Acne Vulgaris: A Thorough ECG Study
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG SB204 4%
- DRUG SB204 8% or 12%
Study Locations (1)
Wisconsin
- Spaulding Clinical Research, LLC - West Bend
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
What the finished NCT02581072 record still lists
NCT02581072 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 3 interventions - of which Vehicle is the first listed.
NCT02581072 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT02581072 about?
NCT02581072 is a clinical study titled "A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204". A Double-Blind, Double-Dummy, Randomized, 4-Period Crossover Study to Define the ECG Effects of SB204 Using a Clinical and Supratherapeutic Dose Compared with Placebo and Moxifloxacin (a Positive Control) in Subjects with Acne Vulgaris: A Thorough ECG Study
What is the current status of trial NCT02581072?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2015-10. Estimated completion is 2016-04.
What conditions does trial NCT02581072 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT02581072?
The interventions under investigation include: Vehicle (DRUG), SB204 4% (DRUG), SB204 8% or 12% (DRUG).
Who is sponsoring clinical trial NCT02581072?
This trial is sponsored by Novan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02581072 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02581072's enrollment target sits among peer trials
56 43rd of 67 higher than 25 of 67 other Acne Vulgaris trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne Vulgaris trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy
RECRUITING · Phase 1
-
Lipidome and Microbiome Profile of Acne
ACTIVE NOT RECRUITING · Phase 1
-
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris
COMPLETED · Phase 1
-
Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
COMPLETED · Phase 1
-
A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers
COMPLETED · Phase 1
-
A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia